An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer

Article Abstract:

The carcinoembryonic antigen (CEA) test may not be an effective method for diagnosis of a recurrence of colon cancer. CEA is a protein secreted by colon cancer cells into the lining of the gastrointestinal tract. Among 1,017 colon cancer patients who were monitored with CEA testing, 417 had a cancer recurrence and 600 did not. An increase in CEA concentration occurred before diagnosis in 59% of the patients who had a cancer recurrence. CEA testing was most sensitive for the detection of metastatic cancer in the liver or in the retroperitoneal space. It was least sensitive for the detection of a cancer recurrence in the colon, lungs or peritoneum, or the lining of the abdominopelvic walls. Sixteen percent of the patients who did not have a cancer recurrence had false-positive CEA test results.

Author: Haller, Daniel G., Macdonald, John S., Moertel, Charles G., Fleming, Thomas R., Laurie, John A., Tangen, Cathy
Care and treatment, Measurement, CEA (Oncology), Carcinoembryonic antigen

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer

Article Abstract:

Chemotherapy with cisplatin can prolong the lives of patients with non-small-cell lung cancer who have their tumor surgically removed, according to a study of 1,867 patients. Five years after this treatment, 44% of those who received cisplatin were alive compared to 40% who did not. Those who received cisplatin also lived longer before their cancer returned.

Evaluation, Drug therapy, Lung cancer, Non-small cell, Non-small cell lung cancer, Cisplatin

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Molecular predictors of survival after adjuvant chemotherapy for colon cancer

Article Abstract:

The loss of chromosome 18q appears to worsen the prognosis of colon cancer whereas a mutation in the gene for transforming growth factor beta1 improves the patient's prognosis. This was the conclusion of a study of 460 patients with colon cancer who had chemotherapy.

Author: Haller, Daniel G., Watanabe, Toshiaki, Wu, Tsung-Teh, Catalano, Paul J., Ueki, Takashi, Satriano, Robert, Benson, Al B., III, Hamilton, Stanley R.
Prognosis

User Contributions:

Comment about this article or add new information about this topic:

CAPTCHA


Subjects list: Colorectal cancer
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.